{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:10:22Z","timestamp":1778227822050,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002467","name":"Dankook University","doi-asserted-by":"publisher","award":["2026"],"award-info":[{"award-number":["2026"]}],"id":[{"id":"10.13039\/501100002467","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11060-026-05546-y","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T14:48:45Z","timestamp":1774709325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel cilengitide derivatives suppress migration and invasion of temozolomide-resistant glioblastoma cells via MAPK\/Akt pathway inhibition"],"prefix":"10.1007","volume":"177","author":[{"given":"Yeonsoo","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujin","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7509-5313","authenticated-orcid":false,"given":"Jiyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"10","key":"5546_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J 352(10):987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J"},{"issue":"11","key":"5546_CR2","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/brainsci13111536","volume":"13","author":"RS Angom","year":"2024","unstructured":"Angom RS, Nakka NMR, Bhattacharya S (2024) Advances in Glioblastoma Therapy: An Update on Current Approaches. Brain Sci 13(11):1536. https:\/\/doi.org\/10.3390\/brainsci13111536","journal-title":"Brain Sci"},{"issue":"1","key":"5546_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","volume":"41","author":"L Rong","year":"2022","unstructured":"Rong L, Li N, Zhang Z (2022) Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res 41(1):142. https:\/\/doi.org\/10.1186\/s13046-022-02349-7","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"5546_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s12032-025-02830-1","volume":"42","author":"F Rizwani","year":"2025","unstructured":"Rizwani F, Patil P, Jain K (2025) Unlocking glioblastoma: breakthroughs in molecular mechanisms and next-generation therapies. Med Oncol 42(7):276. https:\/\/doi.org\/10.1007\/s12032-025-02830-1","journal-title":"Med Oncol"},{"issue":"1","key":"5546_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13148-025-01900-5","volume":"17","author":"M Liu","year":"2025","unstructured":"Liu M, Wang Y, Chen X et al (2025) A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches. Clin Epigenetics 17(1):108. https:\/\/doi.org\/10.1186\/s13148-025-01900-5","journal-title":"Clin Epigenetics"},{"issue":"21","key":"5546_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s44178-022-00021-w","volume":"1","author":"T Yang","year":"2022","unstructured":"Yang T, Shi Y, Liang T et al (2022) Peptide vaccine against glioblastoma: from bench to bedside. Holist Integ Oncol 1(21):1\u201312. https:\/\/doi.org\/10.1007\/s44178-022-00021-w","journal-title":"Holist Integ Oncol"},{"issue":"1","key":"5546_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13041-025-01221-x","volume":"18","author":"R Salahlou","year":"2025","unstructured":"Salahlou R, Farajnia S, Alizadeh E et al (2025) Recent developments in peptide vaccines against Glioblastoma, a review and update. Mol Brain 18(1):50. https:\/\/doi.org\/10.1186\/s13041-025-01221-x","journal-title":"Mol Brain"},{"issue":"4","key":"5546_CR8","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1021\/acs.molpharmaceut.4c01125","volume":"22","author":"R Bellavita","year":"2025","unstructured":"Bellavita R, Barra T, Braccia S et al (2025) Engineering Multifunctional Peptide-Decorated Nanofibers for Targeted Delivery of Temozolomide across the Blood-Brain Barrier. Mol Pharm 22(4):1920\u20131938. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c01125","journal-title":"Mol Pharm"},{"issue":"4","key":"5546_CR9","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/toxins7041079","volume":"7","author":"L Dardevet","year":"2015","unstructured":"Dardevet L, Rani D, Aziz TA et al (2015) Chlorotoxin: a helpful natural scorpion peptide to diagnose glioma and fight tumor invasion. Toxins (Basel) 7(4):1079\u20131101. https:\/\/doi.org\/10.3390\/toxins7041079","journal-title":"Toxins (Basel)"},{"issue":"9","key":"5546_CR10","doi-asserted-by":"publisher","first-page":"104998","DOI":"10.1016\/j.jbc.2023.104998","volume":"299","author":"S Farkas","year":"2023","unstructured":"Farkas S, Cioca D, Mur\u00e1nyi J et al (2023) Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1. J Biol Chem 299(9):104998. https:\/\/doi.org\/10.1016\/j.jbc.2023.104998","journal-title":"J Biol Chem"},{"issue":"5","key":"5546_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3390\/bioengineering12050481","volume":"12","author":"K Jadhav","year":"2025","unstructured":"Jadhav K, Abhang A, Kole EB et al (2025) Peptide-Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress. Bioeng (Basel) 12(5):481. https:\/\/doi.org\/10.3390\/bioengineering12050481","journal-title":"Bioeng (Basel)"},{"issue":"37","key":"5546_CR12","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.2174\/0929867323666160909155222","volume":"23","author":"J Rafferty","year":"2016","unstructured":"Rafferty J, Nagaraj H, McCloskey AP et al (2016) Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients. Curr Med Chem 23(37):4231\u20134259. https:\/\/doi.org\/10.2174\/0929867323666160909155222","journal-title":"Curr Med Chem"},{"issue":"11","key":"5546_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/medicina57111209","volume":"57","author":"D Berillo","year":"2021","unstructured":"Berillo D, Yeskendir A, Zharkinbekov Z et al (2021) Peptide-Based Drug Delivery Systems. Med (Kaunas) 57(11):1209. https:\/\/doi.org\/10.3390\/medicina57111209","journal-title":"Med (Kaunas)"},{"key":"5546_CR14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","volume":"12","author":"E Ruoslahti","year":"1996","unstructured":"Ruoslahti E (1996) RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12:697\u2013715. https:\/\/doi.org\/10.1146\/annurev.cellbio.12.1.697","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"8","key":"5546_CR15","first-page":"813","volume":"40","author":"JA Williams","year":"1992","unstructured":"Williams JA (1992) Disintegrins: RGD-containing proteins which inhibit cell\/matrix interactions (adhesion) and cell\/cell interactions (aggregation) via the integrin receptors. Pathol Biol (Paris) 40(8):813\u2013821","journal-title":"Pathol Biol (Paris)"},{"issue":"10","key":"5546_CR16","first-page":"4213","volume":"32","author":"C Scaringi","year":"2012","unstructured":"Scaringi C, Minniti G, Caporello P et al (2012) Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer Res 32(10):4213\u20134223","journal-title":"Anticancer Res"},{"issue":"8","key":"5546_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2176\/nmc.52.539","volume":"52","author":"K Kurozumi","year":"2012","unstructured":"Kurozumi K, Ichikawa T, Onishi M et al (2012) Cilengitide treatment for malignant glioma: current status and future direction. Neurol Med Chir (Tokyo) 52(8):539\u2013547. https:\/\/doi.org\/10.2176\/nmc.52.539","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"22","key":"5546_CR18","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1002\/cncr.27585","volume":"118","author":"LB Nabors","year":"2012","unstructured":"Nabors LB, Mikkelsen T, Hegi ME et al (2012) New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 118(22):5601\u20135607. https:\/\/doi.org\/10.1002\/cncr.27585","journal-title":"Cancer"},{"issue":"10","key":"5546_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2174\/187152010794728639","volume":"10","author":"C Mas-Moruno","year":"2010","unstructured":"Mas-Moruno C, Rechenmacher F, Kessler H (2010) Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 10(10):753\u2013768. https:\/\/doi.org\/10.2174\/187152010794728639","journal-title":"Anticancer Agents Med Chem"},{"issue":"3","key":"5546_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2217\/fon.11.8","volume":"7","author":"DA Reardon","year":"2011","unstructured":"Reardon DA, Neyns B, Weller M et al (2011) Cilengitide: an RGD pentapeptide \u03b1\u03bd\u03b23 and \u03b1\u03bd\u03b25 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol 7(3):339\u2013354. https:\/\/doi.org\/10.2217\/fon.11.8","journal-title":"Future Oncol"},{"key":"5546_CR21","doi-asserted-by":"publisher","unstructured":"Paolillo M, Serra M, Schinelli S (2016) Integrins in glioblastoma: Still an attractive target? Pharmacol Res 113(Pt A): 55\u201361. https:\/\/doi.org\/10.1016\/j.phrs.2016.08.004","DOI":"10.1016\/j.phrs.2016.08.004"},{"issue":"1","key":"5546_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9\u201322. https:\/\/doi.org\/10.1038\/nrc2748","journal-title":"Nat Rev Cancer"},{"key":"5546_CR23","doi-asserted-by":"publisher","first-page":"639095","DOI":"10.3389\/fphar.2021.639095","volume":"12","author":"J Jeong","year":"2021","unstructured":"Jeong J, Kim J (2021) Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-\u03b21-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells. Front Pharmacol 12:639095. https:\/\/doi.org\/10.3389\/fphar.2021.639095","journal-title":"Front Pharmacol"},{"key":"5546_CR24","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.3390\/ijms23073423","volume":"23","author":"J Jeong","year":"2022","unstructured":"Jeong J, Kim J (2022) Combination Effect of Cilengitide with Erlotinib on TGF-\u03b21-Induced Epithelial-to-Mesenchymal Transition in Human Non-Small Cell Lung Cancer Cells. Int J Mol Sci 23:3423. https:\/\/doi.org\/10.3390\/ijms23073423","journal-title":"Int J Mol Sci"},{"key":"5546_CR25","doi-asserted-by":"publisher","first-page":"e24285","DOI":"10.1002\/pep2.24285","volume":"114","author":"KY Park","year":"2022","unstructured":"Park KY, Jeong J, Kim J (2022) Synthesis and biological evaluation of cilengitide derivatives on TGF-\u03b21-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells. Pep Sci 114:e24285. https:\/\/doi.org\/10.1002\/pep2.24285","journal-title":"Pep Sci"},{"issue":"10","key":"5546_CR26","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/bkcs.12601","volume":"43","author":"M Seo","year":"2022","unstructured":"Seo M, Kim J (2022) Combination effect of cilengitide derivatives with gefitinib on TGF-\u03b21-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells. Bull Korean Chem Soc 43(10):1212\u20131216. https:\/\/doi.org\/10.1002\/bkcs.12601","journal-title":"Bull Korean Chem Soc"},{"key":"5546_CR27","doi-asserted-by":"publisher","first-page":"1277199","DOI":"10.3389\/fphar.2023.1277199","volume":"14","author":"Y Seo","year":"2023","unstructured":"Seo Y, Seo M, Kim J (2023) Effects of cilengitide derivatives on TGF-\u03b21-induced epithelial-to-mesenchymal transition and invasion in gefitinib-resistant non-small cell lung cancer cells. Front Pharmacol 14:1277199. https:\/\/doi.org\/10.3389\/fphar.2023.1277199","journal-title":"Front Pharmacol"},{"key":"5546_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)), Method. Methods 25:402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"5546_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1023\/A:1016119328968","volume":"7","author":"C Soldani","year":"2002","unstructured":"Soldani C, Scovassi AI (2002) Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: An update. Apoptosis 7:321\u2013328. https:\/\/doi.org\/10.1023\/A:1016119328968","journal-title":"Apoptosis"},{"issue":"24","key":"5546_CR30","doi-asserted-by":"publisher","first-page":"9739","DOI":"10.3390\/ijms21249739","volume":"21","author":"GA Cabral-Pacheco","year":"2020","unstructured":"Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C et al (2020) The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. Int J Mol Sci 21(24):9739. https:\/\/doi.org\/10.3390\/ijms21249739","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5546_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.20517\/cdr.2020.79","volume":"4","author":"N Singh","year":"2021","unstructured":"Singh N, Miner A, Hennis L et al (2021) Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist 4(1):17\u201343. https:\/\/doi.org\/10.20517\/cdr.2020.79","journal-title":"Cancer Drug Resist"},{"issue":"7","key":"5546_CR32","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/neuonc\/noae028","volume":"26","author":"HS Cheng","year":"2024","unstructured":"Cheng HS, Chong YK, Lim EKY et al (2024) Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide. Neuro Oncol 26(7):1247\u20131261. https:\/\/doi.org\/10.1093\/neuonc\/noae028","journal-title":"Neuro Oncol"},{"issue":"1","key":"5546_CR33","doi-asserted-by":"publisher","first-page":"14341","DOI":"10.1038\/s41598-024-65398-2","volume":"14","author":"HD Thanh","year":"2024","unstructured":"Thanh HD, Lee S, Nguyen TT et al (2024) Temozolomide promotes matrix metalloproteinase 9 expression through p38 MAPK and JNK pathways in glioblastoma cells. Sci Rep 14(1):14341. https:\/\/doi.org\/10.1038\/s41598-024-65398-2","journal-title":"Sci Rep"},{"issue":"32","key":"5546_CR34","doi-asserted-by":"publisher","first-page":"33755","DOI":"10.18632\/oncotarget.5274","volume":"6","author":"MT Tomicic","year":"2015","unstructured":"Tomicic MT, Meise R, Aasland D et al (2015) Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK\/c-Jun-mediated induction of the BH3-only protein BIM. Oncotarget 6(32):33755\u201333768. https:\/\/doi.org\/10.18632\/oncotarget.5274","journal-title":"Oncotarget"},{"issue":"2","key":"5546_CR35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3892\/ijo.2013.2209","volume":"44","author":"M Okada","year":"2014","unstructured":"Okada M, Sato A, Shibuya K et al (2014) JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. Int J Oncol 44(2):591\u2013599. https:\/\/doi.org\/10.3892\/ijo.2013.2209","journal-title":"Int J Oncol"},{"issue":"1","key":"5546_CR36","doi-asserted-by":"publisher","first-page":"2321770","DOI":"10.1080\/15384047.2024.2321770","volume":"25","author":"Q Sun","year":"2024","unstructured":"Sun Q, Xu J, Yuan F et al (2024) RND1 inhibits epithelial-mesenchymal transition and temozolomide resistance of glioblastoma via AKT\/GSK3-\u03b2 pathway. Cancer Biol Ther 25(1):2321770. https:\/\/doi.org\/10.1080\/15384047.2024.2321770","journal-title":"Cancer Biol Ther"},{"key":"5546_CR37","doi-asserted-by":"crossref","unstructured":"Narayan RS, Fedrigo CA, Brands E et al (2017) The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures. BMC Cancer 17(1):204. https:\/\/link.springer.com\/article\/10.1186\/s12885-017-3193-9","DOI":"10.1186\/s12885-017-3193-9"},{"issue":"10","key":"5546_CR38","doi-asserted-by":"publisher","first-page":"9264","DOI":"10.18632\/aging.205883","volume":"16","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Liang S, Hong Y et al (2024) Bufotalin enhances apoptosis and TMZ chemosensitivity of glioblastoma cells by promoting mitochondrial dysfunction via AKT signaling pathway. Aging 16(10):9264\u20139279. https:\/\/doi.org\/10.18632\/aging.205883","journal-title":"Aging"},{"key":"5546_CR39","doi-asserted-by":"publisher","unstructured":"Thanasupawat T, Natarajan S, Rommel A et al (2017) Dovitinib enhances temozolomide efficacy in glioblastoma cells. Mol Oncol 2017 11(8):1078\u20131098. https:\/\/doi.org\/10.1002\/1878-0261.12076","DOI":"10.1002\/1878-0261.12076"},{"issue":"14","key":"5546_CR40","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.3390\/molecules28145567","volume":"28","author":"S Almutairi","year":"2023","unstructured":"Almutairi S, Kalloush HM, Manoon NA et al (2023) Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013\u20132023). Molecules 28(14):5567. https:\/\/doi.org\/10.3390\/molecules28145567","journal-title":"Molecules"},{"issue":"6","key":"5546_CR41","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.3390\/ijms26062763","volume":"26","author":"M Ballato","year":"2025","unstructured":"Ballato M, German\u00e0 E, Ricciardi G et al (2025) Understanding Neovascularization in Glioblastoma: Insights from the Current Literature. Int J Mol Sci 26(6):2763. https:\/\/doi.org\/10.3390\/ijms26062763","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5546_CR42","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11060-019-03236-6","volume":"144","author":"M Sharma","year":"2019","unstructured":"Sharma M, Schilero C, Peereboom DM et al (2019) Phase II study of Dovitinib in recurrent glioblastoma. J Neurooncol 144(2):359\u2013368. https:\/\/doi.org\/10.1007\/s11060-019-03236-6","journal-title":"J Neurooncol"},{"issue":"1","key":"5546_CR43","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","volume":"180","author":"F Jacob","year":"2020","unstructured":"Jacob F, Salinas RD, Zhang DY et al (2020) A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell 180(1):188\u2013204e22. https:\/\/doi.org\/10.1016\/j.cell.2019.11.036","journal-title":"Cell"},{"key":"5546_CR44","doi-asserted-by":"publisher","unstructured":"Hubert CG, Rivera M, Spangler LC et al (2016) A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Res 76(8):2465-77. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2402","DOI":"10.1158\/0008-5472.CAN-15-2402"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05546-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05546-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05546-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:16:12Z","timestamp":1778224572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05546-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5546"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05546-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human participants or animals. Only the established human glioblastoma cell lines T98G and U87MG were used in the experiments. All methods were carried out in accordance with relevant guidelines and regulations. The T98G (ATCC CRL\u20111690) and U87MG (ATCC HTB\u201114) cell lines were obtained from ATCC and were authenticated and tested for contamination by the provider.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study did not involve human participants or human data; therefore, informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}